Guidelines for Dihydrotestosterone (DHT) for Females
DHT is not recommended for use in women—there are no approved indications, no established dosing guidelines, and no safety data for DHT therapy in females. 1
Current Evidence-Based Recommendations
Testosterone vs. DHT in Women
The available clinical guidelines address testosterone therapy for women, not DHT specifically. The distinction is critical:
The only evidence-based indication for androgen therapy in women is testosterone (not DHT) for postmenopausal women with hypoactive sexual desire disorder (HSDD) after formal biopsychosocial assessment 1
DHT is mentioned in guidelines only as an abbreviation in the context of male androgen metabolism, not as a therapeutic agent for women 2
Why Testosterone, Not DHT?
The 2019 Global Consensus Statement specifically addresses androgens in women and focuses exclusively on testosterone preparations. DHT differs from testosterone in that it cannot be aromatized to estrogen, which may have important implications for bone health, cardiovascular function, and other estrogen-dependent processes in women 3. The lack of aromatization makes DHT a "pure androgen" that bypasses normal physiological androgen-to-estrogen conversion pathways that may be important for women's health.
What About DHEA (Another Androgen)?
Guidelines explicitly recommend against systemic DHEA for postmenopausal women with HSDD, as it is not associated with significant improvement in libido or sexual function (Level IA, Grade A) 1. This further underscores that not all androgens are appropriate for women, even when sexual dysfunction is present.
Clinical Context from Research
Research evidence provides some physiological context:
- Women naturally have higher DHT-to-testosterone ratios (1:4) compared to men (1:13), suggesting different androgen metabolism between sexes 4
- DHT levels in healthy premenopausal women remain relatively stable across the menstrual cycle, while testosterone fluctuates 4
- The clinical significance of this sex difference in DHT metabolism remains unclear and requires further investigation 4
FDA Labeling Perspective
The FDA labeling for DHT preparations explicitly states under Section 5.7 "Use in Women" that these products are contraindicated or not indicated for use in women 5. DHT preparations are formulated and approved exclusively for male hypogonadism.
Common Pitfalls to Avoid
- Do not extrapolate from testosterone guidelines to DHT use—these are different molecules with different physiological effects
- Do not use male DHT formulations off-label in women—there is no safety or efficacy data
- Do not assume that because testosterone has limited approved uses in women, DHT would be similar—the lack of aromatization is a fundamental difference
If Androgen Therapy Is Considered for a Woman
If you are evaluating a postmenopausal woman for potential androgen therapy:
- Use testosterone, not DHT 1
- Confirm diagnosis of HSDD after comprehensive biopsychosocial assessment 1
- Use physiologic doses approximating premenopausal female testosterone concentrations 1
- Measure baseline total testosterone before starting 1
- Recheck testosterone at 3-6 weeks, then every 6 months 1
- Discontinue if no benefit by 6 months 1
- Monitor for signs of androgen excess 1
- Avoid supraphysiologic preparations (pellets, injections) 1
The bottom line: DHT has no established role in female androgen therapy. Stick with testosterone if androgen therapy is indicated for HSDD in postmenopausal women.